Welcome to our dedicated page for Medicus Pharma SEC filings (Ticker: MDCX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Medicus Pharma Ltd. (NASDAQ: MDCX) SEC filings page on Stock Titan provides direct access to the company’s U.S. regulatory disclosures, including registration statements, current reports and financing-related documents. Medicus is an Ontario-incorporated biotech and life sciences company focused on SkinJect™, a doxorubicin microneedle array for basal cell carcinoma, and Teverelix, a long-acting GnRH antagonist for prostate and urologic indications.
Key filing types for MDCX include registration statements on Form S-1, which describe offerings and resale registrations tied to standby equity purchase agreements, warrant exercises and acquisition-related consideration shares. These S-1 filings outline the company’s business, risk factors, pipeline programs and capital structure in detail. Investors can review sections covering the SkinJect™ and Teverelix clinical programs, as well as the terms of equity facilities with counterparties such as YA II PN, Ltd. (Yorkville) and Armistice Capital Master Fund Ltd.
Current reports on Form 8-K document material events such as the acquisition of Antev Limited, warrant inducement agreements, new debenture financings, non-binding memoranda of understanding, and updates on clinical and regulatory milestones. For example, 8-K filings describe the Antev transaction that added Teverelix to the pipeline, the terms of a debenture issued to Yorkville, and inducement arrangements for the exercise of outstanding warrants.
Through this page, users can also monitor unregistered sales of equity securities disclosed under Item 3.02 of Form 8-K, which provide insight into how Medicus funds its clinical development activities. While insider Form 4 reports are not summarized in the provided data, Stock Titan’s platform is designed to surface such ownership changes when available.
How Stock Titan helps
Stock Titan enhances these filings with AI-powered summaries that explain complex documents in plain language, highlight key terms in S-1 and 8-K filings, and point out items relevant to Medicus’s SkinJect™ and Teverelix programs. Real-time EDGAR updates mean new MDCX filings appear quickly, and investors can use this page to track registration statements, financing terms and other regulatory disclosures without reading every page of each filing.
Medicus Pharma Ltd. reported that director Robert J. Ciaruffoli received a stock option grant on December 16, 2025. The option gives him the right to buy 25,000 common shares at an exercise price of $1.8 per share and was granted at no upfront cost.
The option is scheduled to vest quarterly in four equal installments over one year and expires on December 16, 2030. After this grant, he beneficially owns 25,000 stock options, held directly.
Medicus Pharma Ltd. reported that its Chief Scientific Officer, Edward J. Brennan, received a stock option grant covering 50,000 common shares on December 16, 2025. The options have an exercise price of $1.8 per share and expire on December 16, 2030.
The award is scheduled to vest quarterly in four equal installments over one year, and 50,000 derivative securities are listed as beneficially owned directly following the grant.
Medicus Pharma Ltd. reported an equity award for its President and CFO, Carolyn F. Bonner. On December 16, 2025, she received a stock option grant covering 75,000 common shares at an exercise price of $1.8 per share. These options are scheduled to vest quarterly in four equal installments over one year, meaning portions of the grant become exercisable every quarter during that period.
After this grant, she held 75,000 derivative securities directly, all tied to the company’s common shares. This type of award is a common form of equity-based compensation that links an executive’s potential future gains to the company’s share performance.
Medicus Pharma Ltd. (MDCX) reported an equity award to its Chief Executive Officer and director, Raza Bokhari. On December 16, 2025, he received a stock option covering 125,000 common shares with an exercise price of $1.8 per share and an expiration date of December 16, 2030. The option is scheduled to vest quarterly in four equal installments over one year, meaning the award becomes fully vested after that period if service conditions are met. Following the grant, 125,000 derivative securities are shown as beneficially owned with direct ownership.
Medicus Pharma Ltd. reported a new stock option grant to a director. On December 16, 2025, the director received a stock option to buy 25,000 common shares of Medicus Pharma at an exercise price of $1.8 per share, expiring on December 16, 2030.
The option is scheduled to vest quarterly in four equal installments over one year, aligning the director’s potential equity ownership with short-term company performance. Following this grant, the director beneficially owns 25,000 derivative securities, held as a direct ownership position.
Medicus Pharma Ltd. filed a prospectus supplement covering the resale of up to 2,680,000 common shares tied to previously issued warrants. The supplement adds information from a new current report about a warrant inducement agreement and recent equity sales.
On December 5, 2025 the company agreed with an accredited institutional holder to amend existing warrants for up to 2,680,000 common shares to an exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional common shares at $2.00 per share, expiring on June 5, 2031, with one series allowing the company to force exercise if the 10‑day average VWAP reaches $10.00. Gross proceeds from the exercise of the existing warrants are expected to be approximately $5.1 million, before expenses and a 6.0% cash fee to Maxim Group LLC.
The company plans to register the resale of the shares underlying the new warrants by filing a new registration statement within 60 days and keeping it effective until the original holder can sell under Rule 144 without limits. Separately, under its Standby Equity Purchase Agreement with Yorkville, Medicus Pharma sold 680,893 common shares for aggregate consideration of $1,500,905 and used part of the net proceeds to prepay a portion of an outstanding debenture. Its common shares trade on the Nasdaq Capital Market under the symbol MDCX, with a last reported price of $2.05 on December 5, 2025.
Medicus Pharma Ltd. has filed a prospectus supplement relating to 1,115,500 common shares issuable upon the exercise of previously registered warrants and uses it to update investors on new financing activity. The company entered into a warrant inducement agreement with an institutional holder to amend existing warrants to buy up to 2,680,000 common shares at $1.92 per share, in exchange for the holder receiving 4,020,000 new unregistered warrants with a $2.00 exercise price, expiring June 5, 2031. One series of these new warrants allows the company, under certain conditions, to force exercise if the average share VWAP reaches $10.00 over ten trading days, and the company expects approximately $5.1 million in gross proceeds from the existing warrant exercises before a 6% fee to its advisor.
The filing also details recent sales of 680,893 common shares to Yorkville under a standby equity purchase agreement, generating about $1,500,905 in aggregate consideration, with part of the net proceeds used to prepay a portion of a debenture owed to Yorkville. Medicus plans to register the resale of the shares underlying the new warrants in a future registration statement and notes that the new warrants and related shares are currently unregistered, issued under a private offering exemption.
Medicus Pharma Ltd. entered a warrant inducement agreement with an accredited institutional holder to encourage exercise of existing warrants to buy up to 2,680,000 common shares at an amended exercise price of $1.92 per share. In return, the holder will receive new unregistered warrants for up to 4,020,000 additional shares at $2.00 per share, split into two series expiring on June 5, 2031, with one series allowing the company to require exercise if the 10-day average VWAP reaches $10.00.
The company expects approximately $5.1 million in gross proceeds from the exercise of the existing warrants, before fees including a 6.0% cash fee to Maxim Group LLC. Medicus also reported prior sales of 680,893 common shares to Yorkville under a standby equity purchase agreement for approximately $1,500,905 in aggregate, using part of the net proceeds to prepay a portion of an outstanding debenture. The company plans to file a registration statement to permit resale of the new warrant shares.
Medicus Pharma Ltd. updates its prospectus for an offering of up to 2,680,000 common shares and attaches a recent current report. The supplement incorporates a Form 8-K that details executive leadership changes while keeping the original S-1 prospectus in effect.
The company’s common shares trade on Nasdaq under the symbol MDCX, with a last reported price of $1.73 on December 3, 2025. The filing confirms Medicus Pharma’s status as an emerging growth company and reminds investors of the high risks described in the underlying prospectus.
The Form 8-K reports that Chief Financial Officer James Quinlan resigned as an officer and employee effective November 28, 2025, after being on medical leave since September 12, 2025. Effective December 1, 2025, President Carolyn Bonner, who had been acting CFO, was appointed Chief Financial Officer and will continue serving as President under a five-year employment agreement with a $395,000 base salary and escalating target bonus opportunities.
Medicus Pharma Ltd. is registering up to 2,680,000 common shares for resale by Armistice Capital Master Fund Ltd. These shares are issuable upon exercise of 2,680,000 Private Warrants with a $3.75 exercise price and a July 15, 2030 expiry. Medicus is not selling shares itself and will not receive proceeds from any resale, though it may receive up to $10,050,000 if the Private Warrants are exercised.
The company is a clinical-stage life sciences business developing SkinJect™, a dissolvable microneedle patch for basal cell carcinoma, and Teverelix for high‑risk prostate cancer and acute urinary retention. It recently acquired 98.6% of Antev Limited to advance Teverelix and has begun Phase 2 SkinJect™ trials and regulatory initiatives in the U.S. and U.K.
Medicus remains deeply loss‑making, with a net loss of $27.3 million for the nine months ended September 30, 2025 and an accumulated deficit of about $56.2 million, resulting in a shareholders’ deficit and an auditor‑flagged substantial doubt about its ability to continue as a going concern. The company expects to need significant additional financing, faces extensive regulatory and clinical risk, and relies heavily on key licenses and successful integration of Antev. Its shares trade on Nasdaq under “MDCX”.
FAQ
What is the current stock price of Medicus Pharma (MDCX)?
What is the market cap of Medicus Pharma (MDCX)?
